Is Johnson & Johnson a Buy After Its Q1 2026 Earnings Report?
Key Points
Johnson & Johnson exceeded expectations in its Q1 2026 earnings report.
Investors weren't blown away by the results.
The stock price is down over the last several days.
- 10 stocks we like better than Johnson & Johnson ›
Johnson & Johnson (NYSE: JNJ) has had strong momentum over the last year, with shares trading up more than 52%.
After the company's first-quarter 2026 earnings report, however, the response was muted, with the stock price slightly lower following the results' release.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
With momentum temporarily stalling, here's what to consider before investing in Johnson & Johnson.
Image source: Getty Images.
Why J&J's stock price is falling despite positive updates
For Q1 2026, Johnson & Johnson beat estimates, conservatively boosted its guidance for the year, and showed revenue progress from several drugs. Darzalex, its blood cancer treatment, generated roughly $4 billion in sales, while Tremfya, used to treat inflammatory bowel disease and psoriasis, generated $1.6 billion.
While positive, the updates weren't enough to offset a concern shareholders may have. Its drug Stelara, which is used to treat autoimmune diseases, saw its patent expire last year, and sales plummeted from $1.6 billion in Q1 2025 to $656 million in Q1 2026 as competition from generic versions increased.
Is it worth owning shares on the pullback?
In the short term, there likely won't be much news that would move Johnson & Johnson's stock price in either direction.
As a long-term investment, Johnson & Johnson has a promising drug pipeline and has offered stability by increasing its dividend payout for 64 consecutive years. It still has to grow into its forward price-to-earnings ratio, which is higher than in recent quarters, but in terms of mixing stability with upside potential, Johnson & Johnson has a lot to offer.
Should you buy stock in Johnson & Johnson right now?
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $581,304!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,215,992!*
Now, it’s worth noting Stock Advisor’s total average return is 1,016% — a market-crushing outperformance compared to 197% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 18, 2026.
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
Recommended Articles
